228 related articles for article (PubMed ID: 28486273)
61. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes.
Fujie T; Tahara K; Tanaka F; Mori M; Takesako K; Akiyoshi T
Int J Cancer; 1999 Jan; 80(2):169-72. PubMed ID: 9935194
[TBL] [Abstract][Full Text] [Related]
62. Expression of MAGE-A11 in breast cancer tissues and its effects on the proliferation of breast cancer cells.
Xia LP; Xu M; Chen Y; Shao WW
Mol Med Rep; 2013 Jan; 7(1):254-8. PubMed ID: 23064813
[TBL] [Abstract][Full Text] [Related]
63. Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene.
Yoshimura M; Tada Y; Ofuzi K; Yamamoto M; Nakatsura T
Oncol Rep; 2014 Jul; 32(1):33-9. PubMed ID: 24842630
[TBL] [Abstract][Full Text] [Related]
64. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
[TBL] [Abstract][Full Text] [Related]
65. A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model.
Sher YP; Lin SI; Chen IH; Liu HY; Lin CY; Chiang IP; Roffler S; Chen HW; Liu SJ
Oncotarget; 2016 Jan; 7(1):671-83. PubMed ID: 26621839
[TBL] [Abstract][Full Text] [Related]
66. Identification of HLA-A*0201/-A*2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response.
Kawamoto M; Tanaka F; Mimori K; Inoue H; Kamohara Y; Mori M
Oncol Rep; 2011 Feb; 25(2):469-76. PubMed ID: 21165574
[TBL] [Abstract][Full Text] [Related]
67. Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens.
Liu X; Song N; Liu Y; Liu Y; Li J; Ding J; Tong Z
Cell Immunol; 2015 Jun; 295(2):77-82. PubMed ID: 25863743
[TBL] [Abstract][Full Text] [Related]
68. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
Gückel B; Stumm S; Rentzsch C; Marmé A; Mannhardt G; Wallwiener D
Cancer Immunol Immunother; 2005 Feb; 54(2):129-40. PubMed ID: 15365776
[TBL] [Abstract][Full Text] [Related]
69. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J
Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146
[TBL] [Abstract][Full Text] [Related]
70. Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8
Shi W; Qiu Q; Tong Z; Guo W; Zou F; Feng Z; Wang Y; Huang W; Qian H
Eur J Med Chem; 2020 Mar; 189():112051. PubMed ID: 31968280
[TBL] [Abstract][Full Text] [Related]
71. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
[TBL] [Abstract][Full Text] [Related]
72. Identification of novel human leukocyte antigen-A*11:01-restricted cytotoxic T-lymphocyte epitopes derived from osteosarcoma antigen papillomavirus binding factor.
Li D; Toji S; Watanabe K; Torigoe T; Tsukahara T
Cancer Sci; 2019 Apr; 110(4):1156-1168. PubMed ID: 30767336
[TBL] [Abstract][Full Text] [Related]
73. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
Tanaka F; Fujie T; Tahara K; Mori M; Takesako K; Sette A; Celis E; Akiyoshi T
Cancer Res; 1997 Oct; 57(20):4465-8. PubMed ID: 9377553
[TBL] [Abstract][Full Text] [Related]
74. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.
Ottaviani S; Zhang Y; Boon T; van der Bruggen P
Cancer Immunol Immunother; 2005 Dec; 54(12):1214-20. PubMed ID: 16025263
[TBL] [Abstract][Full Text] [Related]
75. Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer.
Filho PA; López-Albaitero A; Xi L; Gooding W; Godfrey T; Ferris RL
Int J Cancer; 2009 Oct; 125(8):1912-20. PubMed ID: 19610063
[TBL] [Abstract][Full Text] [Related]
76. CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.
Tykodi SS; Satoh S; Deming JD; Chou J; Harrop R; Warren EH
J Immunother; 2012 Sep; 35(7):523-33. PubMed ID: 22892449
[TBL] [Abstract][Full Text] [Related]
77. Cross-immunizing potential of tumor MAGE-A epitopes recognized by HLA-A*02:01-restricted cytotoxic T lymphocytes.
Huang ZM; Jia ZC; Tang J; Zhang Y; Tian Y; Ni DJ; Wang F; Wu YZ; Ni B
BMB Rep; 2012 Jul; 45(7):408-13. PubMed ID: 22831976
[TBL] [Abstract][Full Text] [Related]
78. The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytes.
Fleischhauer K; Gattinoni L; Dalerba P; Lauvau G; Zanaria E; Dabovic B; van Endert PM; Bordignon C; Traversari C
Cancer Res; 1998 Jul; 58(14):2969-72. PubMed ID: 9679956
[TBL] [Abstract][Full Text] [Related]
79. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product.
Visseren MJ; van der Burg SH; van der Voort EI; Brandt RM; Schrier PI; van der Bruggen P; Boon T; Melief CJ; Kast WM
Int J Cancer; 1997 Sep; 73(1):125-30. PubMed ID: 9334819
[TBL] [Abstract][Full Text] [Related]
80. MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides.
Bar-Haim E; Paz A; Machlenkin A; Hazzan D; Tirosh B; Carmon L; Brenner B; Vadai E; Mor O; Stein A; Lemonnier FA; Tzehoval E; Eisenbach L
Br J Cancer; 2004 Jul; 91(2):398-407. PubMed ID: 15213716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
